Ardelyx, Inc.
Financials
Valuation Metrics
Ardelyx, Inc.'s Market Cap is $747M. At end of 2025 it was $1.42B. Ranked #2569 of 3,118 in US market (top 82%), #1082 of 1,474 on NASDAQ (top 73%), #196 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $747M | US#2,569/3,118 Sec#196/265 |
| Revenue | $451M | US#2,282/3,118 Sec#80/265 |
| Net Income | $-56M | US—/3,118 Sec—/265 |
| Total Assets | $576M | US#2,703/3,118 Sec#143/265 |
| Net Assets | $149M | US#2,736/3,118 Sec#204/265 |
| Employees | 489 | US#2,272/3,118 Sec#83/265 |
| Value | ||
| P/B | 5.01x | US#2,235/3,118 Sec#144/265 |
| P/S | 1.66x | US#1,126/3,118 Sec#22/265 |
| FCF Yield | -2.40% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -37.38% | US#2,603/3,118 Sec#128/265 |
| ROA | -9.67% | US#2,647/3,118 Sec#100/265 |
| Op. Margin | -7.86% | US#2,494/3,118 Sec#92/265 |
| Revenue Growth | 16.77% | US#821/3,118 Sec#79/265 |
| Financial Health | ||
| Debt Ratio | 286.47% | US#2,068/3,118 Sec#206/265 |
| Total Debt | $256M | US#2,150/3,118 Sec#87/265 |
| FCF | $-18M | US#2,396/3,118 Sec#92/265 |
| Cash | $97M | US#2,250/3,118 Sec#177/265 |
| Current Ratio | 3.34x | US#680/3,118 Sec#177/265 |
| Performance | ||
| 1Y Return | -50.08% | US#2,729/3,118 Sec#221/265 |
| 1M Return | -9.43% | US#2,516/3,118 Sec#185/265 |
| From 52W High | -63.99% | US#2,895/3,118 Sec#229/265 |
| 1Y MDD | -62.45% | US#2,782/3,118 Sec#213/265 |
| Trading | ||
| Volume | 3,904,670 shares | US#665/3,118 Sec#52/265 |
| Trading Value | $12M | US#2,328/3,118 Sec#183/265 |
| Per Share | ||
| EPS | $-0.23 | US—/3,118 Sec—/265 |
| BPS | $0.60 | US#2,739/3,118 Sec#213/265 |
Company Info
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.